Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.49 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.46 |
| ▸ | DAO | P14920 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | MMP2 | P08253 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | COMT | P21964 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28986906 | 0.79 | PARP1 (0.49) | PARP1KCNMA1DAOKDM4EADORA3 | |
| SCHEMBL1983703 | 0.79 | PARP1 (0.49) | PARP1KCNMA1KDM4EADORA3ADORA2A | |
| SCHEMBL3817890 | 0.79 | PARP1 (0.49) | PARP1KCNMA1DAOKDM4EADORA3 | |
| SCHEMBL28893532 | 0.79 | PARP1 (0.49) | PARP1KCNMA1DAOKDM4EADORA3 | |
| SCHEMBL18237558 | 0.75 | PARP1 (0.45) | PARP1KCNMA1KDM4EADORA3ADORA2A | |
| SCHEMBL1681360 | 0.75 | PARP1 (0.45) | PARP1KCNMA1DAOKDM4EADORA3 | |
| SCHEMBL1326106 | 0.73 | PARP1 (0.44) | PARP1KCNMA1KDM4EADORA3ADORA2A | |
| SCHEMBL15375729 | 0.73 | CYP3A4 (0.42) | PARP1KCNMA1KDM4EADORA3NUDT1 | |
| Benzoylenurea SCHEMBL29947820 | 0.72 | ALDH1A1 (0.58) | PARP1DAOKDM4EADORA3TSHR | |
| Benzoylenurea SCHEMBL357451 | 0.72 | ALDH1A1 (0.58) | PARP1DAOKDM4EADORA3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299393-A1 | SMALL MOLECULE DISRUPTORS OF PROTEIN INTERACTIONS IN HISTONE DEACETYLASE COMPLEXES | UNIVERSITY OF LIEGE (BE) | 2024-09-12 | — | — | US | disclosed |
| WO-2022266473-A1 | SMALL MOLECULE DISRUPTORS OF PROTEIN INTERACTIONS IN HISTONE DEACETYLASE COMPLEXES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| US-9163018-B2 | Method of treatment of age-related macular degeneration (AMD) | PRANA BIOTECHNOLOGY INC. (AU) | 2015-10-20 | — | — | US | disclosed |
| EP-2539336-B1 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GMBH (DE) | 2014-10-22 | — | — | EP | disclosed |
| US-8815893-B2 | Hetarylaminonaphthyridines | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-20140088122-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2014-03-27 | — | — | US | disclosed |
| EP-2539336-A2 | HETARYLAMINONAPHTHYRIDINES | Merck Patent GmbH (DE) | 2013-01-02 | — | — | EP | disclosed |
| US-20120316166-A1 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-13 | — | — | US | disclosed |
| WO-2011101069-A2 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GMBH (DE) | 2011-08-25 | — | — | WO | disclosed |
| US-20110071167-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2011-03-24 | — | — | US | disclosed |
| EP-2210892-A2 | Neurologically-active compounds | Prana Biotechnology Limited (AU) | 2010-07-28 | — | — | EP | disclosed |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-24 | — | — | US | disclosed |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-24 | — | — | US | disclosed |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-24 | — | — | US | disclosed |
| US-20100144693-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-10 | — | — | US | disclosed |
| US-7692011-B2 | 8-hydroxy and 8-mercapto quinazolinones | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-04-06 | — | — | US | disclosed |
| US-7692011-B2 | 8-hydroxy and 8-mercapto quinazolinones | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-04-06 | — | — | US | disclosed |
| US-7692011-B2 | 8-hydroxy and 8-mercapto quinazolinones | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-04-06 | — | — | US | disclosed |
| US-20060167000-A1 | Neurologically-active compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167000-A1 | Neurologically-active compounds | ACHE, PSEN1, PSEN2 | PARP1 2866/4885KCNMA1 663/4885DAO 1162/4885 |
| US-20140088122-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | ALDH1A2, AGER, PDE6C | PARP1 1203/4885KCNMA1 3974/4885DAO 1648/4885 |
| US-20240299393-A1 | SMALL MOLECULE DISRUPTORS OF PROTEIN INTERACTIONS IN HISTONE DEACETYLASE COMPLEXES | HDAC1, HDAC6, HDAC10 | PARP1 1520/4885KCNMA1 4023/4885DAO 4020/4885 |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | ACHE, PSEN1, PSEN2 | PARP1 3308/4885KCNMA1 655/4885DAO 1175/4885 |
| US-20100144693-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | ALDH1A2, AGER, PDE6C | PARP1 1203/4885KCNMA1 3974/4885DAO 1648/4885 |
| US-20120316166-A1 | HETARYLAMINONAPHTHYRIDINES | ATP5ME, ATP5F1A, ATP5F1D | PARP1 605/4885KCNMA1 3198/4885DAO 2609/4885 |
| US-20110071167-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | ALDH1A2, AGER, PDE6C | PARP1 1203/4885KCNMA1 3974/4885DAO 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.